Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

Bibliography

• Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 2012;165:1288-305
   PubMed Web of Science ®Google Scholar
• Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90
   PubMed Web of Science ®Google Scholar
• Kehler J, Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 2011;17:137-50
   PubMed Web of Science ®Google Scholar
• Chappie TA, Helal CJ, Hou X. Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition. J Med Chem 2012;55(17):7299-331
   PubMed Web of Science ®Google Scholar
• Kehler J, Kilburn JP. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Patents 2009;19:1715-25
   PubMed Web of Science ®Google Scholar
• Kehler Jan, Ritzen A, Greve DR. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Patents 2007;17:147-58
   Web of Science ®Google Scholar
• H. Lundbeck A/S. WO2009152825; 2009
   Google Scholar
• Kehler J, Ritzen A, Marigo M, 4-Phenyl imidazoles: a novel class of phosphodiesterase 10A (PDE10A) inhibitors as a potential new generation of antipsychotics. Abstracts of Papers, 243rd ACS National Meeting & Exposition; 25 – 29 March 2012; San Diego, CA, United States; 2012; MEDI-296
   Google Scholar
• H. Lundbeck A/S. WO2011072694; 2011
   Google Scholar
• H. Lundbeck A/S. WO2011072695; 2011
   Google Scholar
• H. Lundbeck A/S. WO2011072696; 2011
   Google Scholar
• H. Lundbeck A/S. WO2011072697; 2011
   Google Scholar
• H. Lundbeck A/S. WO2012000519; 2011
   Google Scholar
• H. Lundbeck A/S. WO2012007006; 2011
   Google Scholar
• Asproni B, Murineddu G, Pau A. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg Med Chem 2011;19:642-9
   PubMed Web of Science ®Google Scholar
• Kehler J, Ritzen A, Langgard M. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem Lett 2011;21:3738-42
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. WO2012065612; 2011
   Google Scholar
• Merck. WO2010138430; 2010
   Google Scholar
• Raheem IT, Breslin MJ, Fandozzi C, Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012;22(18):5903-8
   PubMed Web of Science ®Google Scholar
• Smith SM, Uslanerb JM, Cox CD, The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 2013;64(1):215-23
   PubMed Web of Science ®Google Scholar
• Merck. WO2011022213; 2011
   Google Scholar
• Merck. WO2010138585; 2010
   Google Scholar
• Merck. WO2011053559; 2011
   Google Scholar
• Merck. WO2012044561; 2012
   Google Scholar
• Merck. WO2012044562; 2012
   Google Scholar
• Merck. WO2012054366; 2012
   Google Scholar
• Merck. WO2012058133; 2012
   Google Scholar
• Merck (Schering Corp.). WO2010062559; 2010
   Google Scholar
• McElroy WT, Tan Z, Basu K, Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound. Bioorg Med Chem Lett 2012;22:1335-9
   PubMed Web of Science ®Google Scholar
• Ho GD, Yang S-W, Smotryski J, The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg Med Chem Lett 2012;22:1019-22
   PubMed Web of Science ®Google Scholar
• Yang S-W, Smotryski J, McElroy WT, Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg Med Chem Lett 2012;22:235-9
   PubMed Web of Science ®Google Scholar
• Merck (Schering Corp.). WO2010117926; 2010
   Google Scholar
• Merck (N. V. Organon; Schering Corp.). WO2011008597; 2011
   Google Scholar
• Ho GD, Seganish MW, Bercovici A, The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012;22:2585-9
   PubMed Web of Science ®Google Scholar
• Omeros Corp. WO2009143178; 2009
   Google Scholar
• Omeros Corp. WO2010017236; 2010
   Google Scholar
• Gage JL, Onrust R, Johnston D, N-Acylhydrazones as inhibitors of PDE10A. Bioorg Med Chem Lett 2012;21:4155-9
   Web of Science ®Google Scholar
• Cutshall NS, Onrust R, Rohde A, Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. Bioorg Med Chem Lett 2012;22:5595-9
   PubMed Web of Science ®Google Scholar
• Omeros Corp. WO2011112828; 2011
   Google Scholar
• Envivo Pharmaceuticals, Inc. WO2009158473; 2009
   Google Scholar
• Envivo Pharmaceuticals, Inc. WO2009158393; 2009
   Google Scholar
• Envivo Pharmaceuticals, Inc. WO2009158467; 2009
   Google Scholar
• Envivo Pharmaceuticals, Inc. WO2010006130; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. WO2010063610; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. WO2010094762; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. US20110071128; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. WO2011117264; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. US20120142665; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. WO2011089132; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. WO2011154327; 2011
   Google Scholar
• Biotie/Wyeth. WO2010138833; 2010
   Google Scholar
• Malamas MS, Ni Y, Erdei J, Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem 2011;54:7621-38
   PubMed Web of Science ®Google Scholar
• Biotie/Wyeth. WO2010054260; 2010
   Google Scholar
• Biotie/Wyeth. WO2010054253; 2010
   Google Scholar
• Hofgen N, Stange H, Schindler R, Discovery of Imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitors. J Med Chem 2010;5: 4399-411
   Google Scholar
• Biocrea/Boehringer Ingelheim. WO2012104293; 2012
   Google Scholar
• Glenmark Pharmaceuticals Ltd. WO2011132048; 2011
   Google Scholar
• Glenmark Pharmaceuticals Ltd. WO2011138657; 2011
   Google Scholar
• Glenmark Pharmaceuticals Ltd. WO2011132051; 2011
   Google Scholar
• Glenmark Pharmaceuticals Ltd. IN2009MU03042; 2012
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. US20100197651; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2012018059; 2012
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2012018058; 2012
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2012020780; 2012
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2011163355; 2011
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2012018909; 2012
   Google Scholar
• Janssen Pharmaceutica NV, BELG. WO2011051342; 2011
   Google Scholar
• Janssen Pharmaceutica NV, BELG. WO2011110545; 2011
   Google Scholar
• Sunovion Pharmaceuticals, Inc. WO2011150156; 2011
   Google Scholar
• Sunovion Pharmaceuticals, Inc. US20120178748; 2012
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. WO2010027097; 2010
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. WO2010030027; 2010
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. WO2011105628; 2011
   Google Scholar
• Andersen OA, Schoenfeld DL, Toogood-Johnson I, Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure. Acta Crystallogr D Biol Crystallogr 2009;D65(8):872-4
   Google Scholar
• Law R, Barker O, Barker JJ, The multiple roles of computational chemistry in fragment-based drug design. J Comput Aided Mol Des 2009;23:459-73
   PubMed Web of Science ®Google Scholar
• Evotec (UK) Ltd. WO2012019954; 2012
   Google Scholar
• Amgen, Inc. WO2010057126; 2010
   Google Scholar
• Amgen, Inc. WO2010057121; 2010
   Google Scholar
• Amgen, Inc. US20100160280; 2010
   Google Scholar
• Amgen, Inc. WO2011143365; 2011
   Google Scholar
• Amgen, Inc. WO2011143366; 2011
   Google Scholar
• Amgen, Inc. WO2011143495; 2011
   Google Scholar
• Amgen, Inc. WO2011143129; 2011
   Google Scholar
• Janssen Pharmaceutica NV. WO2010097367; 2010
   Google Scholar
• Janssen Pharmaceutica NV. WO2011051324; 2011
   Google Scholar
• Celen S, Koole M, De AM, Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010;51:1584-91
   PubMed Web of Science ®Google Scholar
• Andres J-I, Angelis MD, Alcazar J, Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem 2011;54:5820-35
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. WO2010138577; 2010
   Google Scholar
• H. Lundbeck A/S. WO2012062319; 2012
   Google Scholar
• Tu Z, Xu J, Jones LA, Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol 2010;37:509-16
   PubMed Web of Science ®Google Scholar
• Tu Z, Fan J, Li S, Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem 2011;19:1666-73
   PubMed Web of Science ®Google Scholar
• Funke U, Deuther-Conrad W, Schwan G, Radiosynthesis and radiotracer properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for imaging of phosphodiesterase 10A with PET. Pharmaceuticals 2012;5:169-88
   Google Scholar
• Hu E, Ma J, Biorn C, Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem 2012;5:4776-87
   Google Scholar
• AstraZeneca. Bauer U, Giordanetto F, Bauer M. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. Bioorg Med Chem Lett 2012;22:1944-8
   PubMed Web of Science ®Google Scholar
• DeMartinis N, Banerjee A, Kumar V, Results of a Phase 2a Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. Society of Biological Psychiatry 67th Annual Scientific Convention & Meeting; 3 – 5 May 2012; Sheraton Philadelphia Downtown Hotel – Philadelphia, Pennsylvania
   Google Scholar